On August 26, GENSCRIPT BIO rose 3.03% in regular trading, trading at HK$35.84/share, with turnover of HK$456 million.

On the news front, the CXO sector continues to benefit from improving industry conditions as global biopharma investment and financing recovery accelerates innovative drug R&D spending, lifting sector stocks broadly. Following the company's interim results release, multiple institutions have intensified bullish coverage. JPMorgan raised its target price to HK$35, Huatai Securities assigned a target of HK$36.08, while BOCOM International and CICC both lifted targets above HK$32, maintaining buy ratings.

The company reported H1 revenue of US$404 million, up 27.3% year-over-year, with AIDD-related business achieving over 100% growth. Adjusted net profit surged 203.3% to US$62.5 million. The life sciences segment posted revenue of US$319 million with adjusted operating profit doubling to US$94 million, driven by AI-powered drug discovery demand, automation upgrades, and client expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)